NASDAQ:ALGS Aligos Therapeutics Q1 2026 Earnings Report $5.61 -0.13 (-2.26%) As of 12:57 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aligos Therapeutics EPS ResultsActual EPS-$2.21Consensus EPS -$2.29Beat/MissBeat by +$0.08One Year Ago EPSN/AAligos Therapeutics Revenue ResultsActual Revenue$2.83 millionExpected Revenue$0.25 millionBeat/MissBeat by +$2.58 millionYoY Revenue GrowthN/AAligos Therapeutics Announcement DetailsQuarterQ1 2026Date5/7/2026TimeAfter Market ClosesConference Call DateThursday, May 7, 2026Conference Call Time4:00PM ETUpcoming EarningsAligos Therapeutics' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 4, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aligos Therapeutics Earnings HeadlinesAligos Therapeutics Presents Positive Phase 1 Data for Pevifoscorvir Sodium at EASL Congress 2026, Suggesting Reduced cccDNA Reservoir in Chronic HBV PatientsMay 27 at 3:10 AM | quiverquant.comQAligos Therapeutics Presents Positive Data at the EASL Congress 2026May 27 at 2:30 AM | globenewswire.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 27 at 1:00 AM | Brownstone Research (Ad)Cantor Fitzgerald initiates coverage of Aligos Therapeutics (ALGS) with overweight recommendationMay 22, 2026 | msn.comWall Street Zen Upgrades Aligos Therapeutics (NASDAQ:ALGS) to "Hold"May 17, 2026 | americanbankingnews.comAligos Therapeutics Announces Ten Abstracts Accepted for Presentation at EASL Congress 2026May 13, 2026 | quiverquant.comQSee More Aligos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email. Email Address About Aligos TherapeuticsAligos Therapeutics (NASDAQ:ALGS) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections. Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners. The company’s lead program for chronic hepatitis B (CHB) employs a combination approach to silence viral genes and stimulate immune clearance. In parallel, Aligos is progressing antiviral candidates for respiratory viruses, including coronaviruses and influenza, by targeting key viral enzymes and immune pathways. Aligos’s clinical development strategy emphasizes combination regimens that may offer functional cures rather than life‐long treatment. Its respiratory virus portfolio includes direct‐acting antivirals targeting viral polymerases, alongside immune modulators intended to enhance host defense mechanisms. By integrating novel chemistries with established antiviral targets, the company aims to deliver differentiated therapies across multiple indications. With clinical trials conducted in North America and partnerships extending to global research centers, Aligos is focused on generating robust data to support regulatory filings. The management team brings deep experience in antiviral drug development, clinical operations and regulatory strategy, positioning the company to advance its mission of developing innovative solutions for patients living with chronic and acute viral diseases.View Aligos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Zscaler Stock Drops 30%: Why the Dip Is a Buy OpportunityRecord Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy?Micron’s $1 Trillion Memory Melt-UpAutoZone's Pullback Sets Up a Long-Term Buying OpportunityAST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in FocusPowerhouse Williams-Sonoma Heading to Fresh Highs in 2026Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound Upcoming Earnings Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026)Dell Technologies (5/28/2026)Royal Bank Of Canada (5/28/2026)Toronto Dominion Bank (5/28/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
